<DOC>
	<DOCNO>NCT01571570</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability short-term safety tolerability TMC435 follow administration 3 single oral dos 150 mg , give different formulation healthy adult participant . In addition , study assess acceptability taste liquid formulation .</brief_summary>
	<brief_title>A Study Assess Bioavailability &amp; Food Effect Different Liquid Capsule Formulations TMC435 .</brief_title>
	<detailed_description>TMC435 investigate treatment chronic hepatitis C infection . The current study Phase I , open-label ( participant investigator know name medication give certain moment ) , randomize ( study medication assign chance ) study design assess relative bioavailability food effect 2 liquid formulation TMC435 , currently develop potential pediatric use , compare Phase III 150 mg capsule . Also new capsule concept formulation investigate comparison Phase III 150 mg capsule . The study perform healthy adult participant divide 3 panel . Participants randomize within panel . Each participant receive 3 different treatment accord classical 6-sequence , 3-period Williams design . In Panel 1 Panel 2 , single oral dose 150 mg TMC435 oral suspension respectively strength compare capsule use Phase III . In Panel 3 , two different capsule concept formulation compare capsule use Phase III . In panel contain liquid , formulation compare fast fed condition investigate food effect . In treatment , participant receive medication Day 1 treatment . There washout period least 7 day subsequent treatment . The main focus trial pharmacokinetic characteristic formulation ( level-profile TMC435 time blood stream ) . This evaluation require multiple blood sample Day 1 till Day 4 treatment . Safety assessment ( blood urine test , blood pressure , pulse , electrocardiogram , physical examination ) follow different schedule evaluate signing Informed Consent Form onwards last trial-related visit throughout study .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Healthy volunteer healthy basis physical examination , medical history , laboratory test , 12lead electrocardiogram vital sign , perform screening , body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include nonsmoking least 3 month prior screen . Women must postmenopausal least 2 year and/or surgically sterile heterosexually active duration trial . All participant know allergy , hypersensitivity intolerance TMC435 excipients . Use concomitant medication , include counter product , herbal medication dietary supplement , except paracetamol ( acetaminophen ) ibuprofen . Any condition , opinion investigator , would compromise study wellbeing participant prevent subject meeting performing study requirement . History suspicion current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise participant 's safety and/or compliance trial procedure . Participation investigational drug trial TMC435 . Infected HIV Hepatitic A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Food effect</keyword>
	<keyword>Capsule</keyword>
	<keyword>Formulations</keyword>
	<keyword>Liquid formulation</keyword>
	<keyword>Concept K</keyword>
	<keyword>Concept L</keyword>
	<keyword>Oral suspension</keyword>
	<keyword>Oral solution</keyword>
	<keyword>TMC435HPC1002</keyword>
	<keyword>TMC435</keyword>
	<keyword>HPC</keyword>
</DOC>